Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across the broader IIM spectrum. EXTON, PA, October 10, 2025 – Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis
New research reveals cautious optimism as physicians weigh transformative potential against safety, access, and the enduring role of biologics and advanced systemics across rheumatic conditions. EXTON, PA, October 6, 2025 – Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists
New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and hemophilia. October 2, 2025 [Exton, PA] – According to the newly released Special Topix™: Adoption and Impact of Gene Therapy in Hematology,
The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake. Exton, PA, October 2, 2025 – Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis
Ultomiris (AZ/Alexion) and Empaveli (Appellis) identified as driving greater PNH treatment flexibility and individualized care Exton, PA, September 26, 2025 – Spherix Global Insights today announced the latest quarterly update to its RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) service, revealing how patient requests and physician perspectives are reshaping the treatment landscape. This update
Spherix Global Insights finds majority of specialists expect Rinvoq’s uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. EXTON, PA, September 25, 2025 – Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy,
As patients struggle with treatment burdens and suboptimal outcomes, new pipeline therapies spark hope for meaningful transformation across nAMD, DME, GA, and UME. Exton, PA, August 28, 2025 — In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 (US), research from Spherix Global Insights with U.S. ophthalmologists,
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. Exton, PA, August 28, 2025 – The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH) represents a critical step forward in a condition with a
New patient chart audit uncovers rising wave of patient-driven treatment switches in ulcerative colitis and Crohn’s disease, opening the door for brands to accelerate market share gains. Exton, PA, August 26, 2025 – Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever
TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity. EXTON, PA, August 25, 2025 – According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar
Breakthrough therapies targeting APOL1 and reducing steroid dependence could redefine treatment standards for FSGS EXTON, PA, August 21, 2025 —The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection point. New data from Spherix Global Insights’ seventh annual Market Dynamix™:
EXTON, PA, August 19, 2025 – Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical stakeholders with critical, forward-looking intelligence into payer priorities, strategies, and evolving access dynamics across a broad range of therapeutic categories. The report will be delivered to
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics’ Casgevy holding a competitive edge over bluebird bio’s Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, August 14, 2025 — As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON, PA, August 7, 2025 – Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), and
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights. Exton, PA, August 6, 2025 – The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, August 6, 2025 — According to the latest findings from Spherix Global Insights’
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
